Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?

Nature Clinical Practice Urology volume 2, pages 18–19 (2005)Cite this article

Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520

boxed-text

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512

    Article  CAS  Google Scholar 

  2. Beer TM et al. (2004) Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 91: 1425–1427

    Article  CAS  Google Scholar 

  3. Joly F and Tannock IF (2004) Chemotherapy for patients with hormone refractory prostate cancer. Ann Oncol 15: 1582–1584

    Article  CAS  Google Scholar 

  4. Petrylak DP (2004) Treatment options for advanced and high-risk prostate cancer. In Proceedings of the Changing Paradigms in Prostate Cancer Symposium: 2004 October 9; London

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Head of the Department of Oncology at Assaf Harofeh Medical Center, Zerifin, Israel

    Avishay Sella

Authors
  1. Avishay Sella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Avishay Sella.

Ethics declarations

Competing interests

The author has provided docetaxel for use in a neoadjuvant trial in localized prostate cancer with poor prognosis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sella, A. Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?. Nat Rev Urol 2, 18–19 (2005). https://doi.org/10.1038/ncpuro0064

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0064

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing